Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer.

导出 OA

翻译打印收藏纠错

作者： Hiroaki,Taniguchi ^[1] ; Daisuke,Hoshino ^[2] ; Chiharu,Moriya ^[1] ; Hitoshi,Zembutsu ^[3] ; Nobuhiro,Nishiyama ^[4] ; Hiroyuki,Yamamoto ^[5] ; Kazunori,Kataoka ^[6] ; Kohzoh,Imai ^[1]

作者单位： The Center for Antibody and Vaccine Therapy, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ^[1] Cancer Biology Department, The Kanagawa Cancer Center Research Institute, Kanagawa 241-0815, Japan. ^[2] Division of Genetics, National Cancer Center Research Institute, Tokyo 104-0045, Japan. ^[3] Polymer Chemistry Division, Chemical Resources Laboratory, Tokyo Institute of Technology, Kanagawa 226-8503, Japan. ^[4] Department of Gastroenterology and Hepatology, School of Medicine, St. Marianna Medical University, Kanagawa 216-0015, Japan. ^[5] Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, Tokyo 113-8656, Japan. ^[6] The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ^[7]

关键词 PRDM14 breast cancer stem cell cancer stemness epigenetic alterations nucleic acid medicine